
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals is a fundamentally sound company with a strong commercial portfolio and a focus on addressing high unmet medical needs. Its well-established drugs, HETLIOZ and Fanapt, have shown consistent revenue growth, and the company's pipeline options for schizophrenia, bipolar disorder, and MDD, as well as its legacy portfolio and cash on hand, contribute to a positive outlook for future growth. Additionally, Vanda has multiple potential regulatory catalysts approaching, including an FDA approval decision for its GPP treatment and ongoing trials for other indications. The application of a discounted cash flow analysis yields a price objective of $21 per share, which is significantly higher than the current stock price. However, risks such as slower sales traction, generic erosion, and negative pricing developments should be considered.
Bears say
Vanda Pharmaceuticals is facing several challenges that could negatively impact its stock performance. The company missed revenue expectations in the second quarter due to timing issues, and its cash balance has decreased. The company's reliance on one product, Fanapt, for the majority of its revenue also increases its vulnerability to shifts in market trends and competition. Additionally, the company faces potential commercial and financial risks related to its pipeline development, and its financial outlook for the next few years appears unfavorable.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares